Results 241 to 250 of about 489,862 (290)

Tumor Lysis Syndrome in a Patient with BRAF^V600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib. [PDF]

Intern Med
Kasai S, Sato E, Sakaguchi C, Sasaki Y.
europepmc   +1 more source

Endocytic Control of Cell‐Autonomous and Non‐Cell‐Autonomous Functions of p53

Advanced Science, EarlyView.
NUMB Ex3‐containing isoforms localize to the plasma membrane, where they recruit p53 through SNX9 and direct it to multivesicular bodies and exosomes. Exported p53 is taken up by neighboring cells and activates nuclear programs, revealing an intercellular, exosome‐based pathway that might help establish a tumor‐suppressive microenvironment.
Roberta Cacciatore, Andrea Basile, Stefano Freddi, Irene Schiano Lomoriello, Carlo Ribelle Zucca, Giuseppe Ciossani, Luigi Scietti, Alessandro Cuomo, Simona Ronzoni, Simone Pelicci, Mario Faretta, Elena Zaccheroni, Giuliana Pelicci, Vittoria Matafora, Angela Bachi, Rosalind Helen Gunby, Salvatore Pece, Sara Sigismund, Letizia Lanzetti, Ivan Nicola Colaluca, Pier Paolo Di Fiore   +20 more
wiley   +1 more source

Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice. [PDF]

Cancer Rep (Hoboken)
Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang N.   +8 more
europepmc   +1 more source

Palmitoylation‐Mediated Ubiquitination of SRPK1 Regulates Ferroptosis in High‐Fat‐Induced Erectile Dysfunction

Advanced Science, EarlyView.
Elevated exogenous palmitic acid promotes the S‐palmitoylation of SRPK1 in endothelial cells, a dynamic process governed by ZDHHC24 and APT1. This post‐translational modification strengthens the interaction between SRPK1 and the E3 ubiquitin ligase MIB1, thereby facilitating the proteasomal degradation of SRPK1.
Xiao‐Hui Tan, Ke‐Fan Li, Yi‐Ming Yuan, Man‐Cheng Xia, Fang‐Zhou Zhao, Hong‐Gang Ying, Zhuo Zhou, Peng‐Chao Gao, Guo‐Qing Xie, Xue‐Song Li, Hui Jiang, Rui‐Li Guan   +11 more
wiley   +1 more source

Tumor lysis syndrome following letrozole for locally advanced breast cancer: a case report. [PDF]

Surg Case Rep
Kikuchi M, Miyabe R, Matsushima H, Kita H, Kobayashi J, Ando T, Atsuta K, Shintani T.   +7 more
europepmc   +1 more source

Spontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report. [PDF]

BMC Pediatr
Pan S, Shen Q, Zhou J, Li T.
europepmc   +1 more source

Effectiveness of a Single Fixed Dose of 3 mg Rasburicase for the Prevention and Management of Hyperuricemia in Tumor Lysis Syndrome in Adults With Cancer. [PDF]

Cureus
Bakhsh S, Khan MA, Alshamrani M, Mufti R, Naeem A, AlMansour M, Alsaeed A, Alahmari M, Aseeri M.   +8 more
europepmc   +1 more source

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database. [PDF]

Front Pharmacol
Xia S, Xu JW, Yan KX, Noguchi Y, Sarangdhar M, Yan M.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor Lysis Syndrome

Clinical Journal of Oncology Nursing, 2004
Tumor lysis syndrome (TLS) is an oncologic emergency characterized by electrolyte and metabolic disturbances that most commonly are associated with lymphoproliferative malignancies and chemotherapy administration. It is manifested by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia.
Diane Cope, Jeannine M. Brant
  +6 more sources

Tumor Lysis Syndrome

Advances in Chronic Kidney Disease, 2021
Tumor lysis syndrome (TLS) is an oncologic emergency due to massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Clinical presentation is characterized by hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Acute kidney injury due to tumor lysis is potentiated
Tarek Barbar, Insara Jaffer Sathick
openaire   +2 more sources